The original innovation ability of biotechnology has improved rapidly.
In recent years, China has successively achieved a number of original innovation achievements at the international leading level in the field of biotechnology, and its original innovation ability has been significantly improved-
The level of academic papers has improved rapidly. During the Tenth Five-Year Plan period, Chinese scientists in the field of biology published more than 30 papers in top international academic journals such as Nature, Science and Cell. In particular, Chinese scientists broke the embarrassing silence that Cell has not published papers for more than 20 years, and published five papers in succession in 2005 alone.
The number of invention patent applications has increased rapidly. During the Ninth Five-Year Plan period, there were 455 patent applications in the field of biotechnology under the 863 Program, including international patent 10; During the Tenth Five-Year Plan period, the total number of patent applications reached 5 182, including 456 international patents, with an alarming increase.
Actively participate in major international scientific projects. Since the Tenth Five-Year Plan, China has participated in the "International Human Single Nucleotide Polymorphism Mapping Project" and completed the work of 10% with high quality. In 2004, scientists in China initiated and led the "International Human Liver protein Group Project". China has become an important force in the field of international biotechnology.
Biotechnology strongly supports agricultural development.
In recent years, China's major breakthrough in the field of biotechnology has provided strong support for agricultural development. This feature is most obvious in the field of super hybrid rice and insect-resistant cotton.
In recent five years, China * * * has bred 60 super hybrid rice combinations that have passed the examination and approval, of which 7 new combinations have reached the yield acceptance of 800 kilograms per mu; Popularize super hybrid rice10.50 million mu, and increase rice by 7.5 million tons based on 50 kg per mu.
During this period, more than 30 new insect-resistant transgenic cotton varieties were obtained in China, with a cumulative extension area of 65.438+0.2 billion mu, reducing the use of pesticides by 50,000 tons and obtaining economic benefits of 65.438+0.6 billion yuan. It is particularly noteworthy that the promotion area of domestic insect-resistant cotton varieties with independent intellectual property rights has greatly exceeded that of imported varieties from the United States.
The situation of insufficient innovation in the pharmaceutical industry has initially changed.
Driven by the National 863 Program, the level of China's biomedical industry has greatly improved in recent years: 45 innovative drugs with independent intellectual property rights have been approved for listing, 4 1 new drug certificates are being declared, 109 drugs have been approved for clinical trials, and 206 candidate innovative drugs are about to complete laboratory research.
The breakthrough of biotechnology has not only initially changed the passive situation of insufficient innovation ability of China's pharmaceutical industry, but also led to the formation of a modern biomedical industry of nearly 60 billion yuan:
-The recombinant human p53 adenovirus injection product independently developed by Chinese enterprises is the first gene therapy product approved for marketing in China and even in the world, which has created a new situation in tumor gene therapy.
-"Tylote", the only new antidiabetic drug with independent intellectual property rights developed by experts in China, was officially launched, and its sales volume continued to rise.
-Recombinant staphylokinase for injection, jointly developed by several units, is used for clinical treatment of various thrombi. It is the first registered and approved recombinant staphylokinase thrombolytic drug in the world and will soon enter clinical use.
-The self-developed sars vaccine is the first in the world to complete 1 clinical trials; The scientific and technological research on AIDS prevention and treatment has achieved initial results, and two therapeutic vaccines have been approved for clinical trials; The human avian influenza vaccine developed in China will soon complete the 1 phase clinical trial, and its safety has been preliminarily verified.
-A number of tissue engineering products and stem cell therapy technologies have been successfully developed, which is expected to usher in a new era of "regenerative medicine" in China. Among them, "tissue engineering skin" will soon obtain a production license and become the first tissue engineering product approved for listing in China; "Primitive Mesenchymal Stem Cell Injection in the Treatment of Hematological Tumors" has started 1 clinical trial, which is expected to make a breakthrough in the field of stem cell therapy.
China biochip appears in the international market.
According to the Ministry of Science and Technology, in recent years, China has established five biochip R&D and industrialization bases in Beijing, Shanghai, Shaanxi, Tianjin and Nanjing, initially forming a biochip R&D pattern with five bases as the core. After five years of vigorous cultivation, biochip industry, a new industry with high technology content and added value, has begun to take shape in China, and some products have begun to enter the international market.
In the past five years, China has successfully developed more than 200 kinds of biochip products, 6 kinds of biochips and related equipment have obtained certificates of new drugs or medical devices, and 9 scientific and technological achievements have won various scientific and technological awards from the state, provinces and municipalities. Among them, Boao's chip scanners have been exported to the European Union and the United States, with sales of biochips and services reaching 200 million yuan, and technology transfer and export reaching nearly 70 million yuan.
In addition, China has initially established a series of active biochip technology platforms with a number of internationally authorized patents, and achieved original results in some aspects, with good international competitiveness. At present, some well-known European and American professional biotechnology companies need to use the patented technology owned by China in product research and development.